Under the direction of Dr. Guru Subramanian Guru Murthy at the Medical College of Wisconsin Cancer Center, the trial ( NCT06502145) will evaluate the safety, tolerability, and recommended Phase II ...
Some results have been hidden because they may be inaccessible to you